Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Observer Bermuda.
Press releases published on September 9, 2025
24/7 Market News: Ken Le, Not Stan Lee, to Lead Prodigy Silk’s Super Fiber Deliveries to Global Brands for Kraig Labs
GlobeNewswire
·
September 9, 2025
DENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, analyses Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the …
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
GlobeNewswire
·
September 9, 2025
HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious dose level Program has addressed key challenges …
Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer
GlobeNewswire
·
September 9, 2025
HORGEN, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, today announced that David Urech, Ph.D., Chief …
Hydrafacial Launches Inaugural Hydrafacial Advisory Councils & Ambassador Network to Fuel Next-Era Innovation and Growth
GlobeNewswire
·
September 9, 2025
LONG BEACH, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announces the launch of the Hydrafacial Advisory Councils and Ambassador Network – a prestigious collective of …
American Oncology Network and Low Country Cancer Care Welcome Dr. Anton Juncaj
GlobeNewswire
·
September 9, 2025
Medical oncologist joins Low Country Cancer Care’s physician team SAVANNAH, Ga., Sept. 09, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing networks of community-based oncology practices, and its partner …
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
GlobeNewswire
·
September 9, 2025
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Confirmed overall response rate (cORR) 68.2% and duration of response (DOR) 14.6 months by BICR in first-line …
Hyperion DeFi Strengthens Leadership Team With Key Appointments to Accelerate DeFi Strategy
GlobeNewswire
·
September 9, 2025
Hyunsu Jung Named Interim CEO; CFO Appointment Confirmed, Underscoring Focus on Decentralized Finance Board Expansion and Continued Strategic Advisory Designed to Drive Growth and Execution LAGUNA HILLS, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Hyperion …
Peer Leadership and Resilience Shine in Military Veteran Alpine Challenge
GlobeNewswire
·
September 9, 2025
WHISTLER, British Columbia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- On September 6th, the fourth annual Military Veteran Alpine Challenge (MVAC) was successfully completed in Whistler, British Columbia. Led by the Chronic Pain Centre of Excellence for Canadian …
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
·
September 9, 2025
HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained …
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
GlobeNewswire
·
September 9, 2025
Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, “ …
Sutter Health Named Among Top 5 Best Workplaces for Innovators by Fast Company
GlobeNewswire
·
September 9, 2025
San Francisco, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sutter Health has been recognized by Fast Company as one of America’s Best Workplaces for Innovators in 2025. Sutter ranked fourth on the list of just 100 top businesses and organizations that empower their …
Aveanna to Participate at the Jefferies Healthcare Services Conference
GlobeNewswire
·
September 9, 2025
ATLANTA, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Jefferies Healthcare Services Conference in Nashville on September 30, 2025. Management will …
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
GlobeNewswire
·
September 9, 2025
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine cohort move toward normal aging profiles …
MAPS Board of Directors Names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors
GlobeNewswire
·
September 9, 2025
Betty Aldworth and Ismail Lourido Ali bring decades of combined experience in drug policy leadership, psychedelic advocacy, and movement building As Co-Executive Directors, Aldworth and Ali reflect MAPS' legacy commitment to serving and strengthening the …
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
GlobeNewswire
·
September 9, 2025
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE …
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
GlobeNewswire
·
September 9, 2025
GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to …
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
GlobeNewswire
·
September 9, 2025
HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that …
Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments
GlobeNewswire
·
September 9, 2025
MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to …
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
GlobeNewswire
·
September 9, 2025
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year analysis, consistent efficacy was observed …
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
GlobeNewswire
·
September 9, 2025
- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused …